Aimei Health Technology Co., Ltd. (AFJK): debt financing — Aimei Health extends business combination deadline to March 6, 2026; issues $34,331 promissory note

Aimei Health Technology Co., Ltd.

Deposited $34,330.96 into trust account to extend combination deadline by one month from Feb 6 to March 6, 2026 (fifteenth extension).
Issued unsecured promissory note to Aimei Health Ltd and United Hydrogen Group; funds equally divided ($17,165.48 each).
Note bears no interest; principal due upon business combination closing or convertible into private units at $10/unit.
Company still seeks initial business combination; trust funds remain reserved for public shareholders only.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.95

Aimei Health Technology Co., Ltd. incurred loan of $34,330.96 with Aimei Health Ltd and United Hydrogen Group Inc. at does not bear interest maturing due and payable upon the date on which the Company consummates a business combination.

Instrument: loan
Principal: $34,330.96
Counterparty: Aimei Health Ltd and United Hydrogen Group Inc.
Rate: does not bear interest
Maturity: due and payable upon the date on which the Company consummates a business combination
Event: incurrence

Exact text from the filing

the Company issued, on February 12, 2026, an unsecured promissory note in the total principal amount of $34,330.96 (the “ Promissory Note ”) to Aimei Health Ltd, a Cayman Islands exempted company (the “ Sponsor ”) and United Hydrogen Group Inc., an exempted company with limited liability incorporated in the Cayman Islands

View on SEC.gov

Browse all debt financings →

Aimei Health Technology Co., Ltd. filing history →

Source: SEC EDGAR

accession 0001493152-26-006694

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.